CD4 Human shRNA Plasmid Kit (Locus ID 920)

Specifications

Product Data
Locus ID	920
Synonyms	CD4mut; IMD79; OKT4D
Vector	pRS
E. coli Selection	Ampicillin
Mammalian Cell Selection	Puromycin
Format	Retroviral plasmids
Kit Components	CD4 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 920). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq	NM_000616, NM_001195014, NM_001195015, NM_001195016, NM_001195017, NR_036545, NM_000616.1, NM_000616.2, NM_000616.3, NM_000616.4, NM_001195015.1, NM_001195015.2, NM_001195014.1, NM_001195014.2, NM_001195016.1, NM_001195016.2, NM_001195017.1, NM_001195017.2, BC025782, BC025782.1, NM_001195016.3, NM_001195017.3, NM_001195014.3, NM_001195015.3
UniProt ID	P01730
Summary	This gene encodes the CD4 membrane glycoprotein of T lymphocytes. The CD4 antigen acts as a coreceptor with the T-cell receptor on the T lymphocyte to recognize antigens displayed by an antigen presenting cell in the context of class II MHC molecules. The CD4 antigen is also a primary receptor for entry of the human immunodeficiency virus through interactions with the HIV Env gp120 subunit. This gene is expressed not only in T lymphocytes, but also in B cells, macrophages, granulocytes, as well as in various regions of the brain. The protein functions to initiate or augment the early phase of T-cell activation, and may function as an important mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system. Multiple alternatively spliced transcript variants encoding different isoforms have been identified in this gene. [provided by RefSeq, May 2020]
shRNA Design	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact tech@clinisciences.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
Performance Guaranteed	OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at tech@clinisciences.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).